215 related articles for article (PubMed ID: 24307563)
21. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Provenzale D; Gupta S; Ahnen DJ; Markowitz AJ; Chung DC; Mayer RJ; Regenbogen SE; Blanco AM; Bray T; Cooper G; Early DS; Ford JM; Giardiello FM; Grady W; Hall MJ; Halverson AL; Hamilton SR; Hampel H; Klapman JB; Larson DW; Lazenby AJ; Llor X; Lynch PM; Mikkelson J; Ness RM; Slavin TP; Sugandha S; Weiss JM; Dwyer MA; Ogba N
J Natl Compr Canc Netw; 2018 Aug; 16(8):939-949. PubMed ID: 30099370
[TBL] [Abstract][Full Text] [Related]
22. Proven Strategies for Increasing Adherence to Colorectal Cancer Screening.
Butterly LF
Gastrointest Endosc Clin N Am; 2020 Jul; 30(3):377-392. PubMed ID: 32439077
[TBL] [Abstract][Full Text] [Related]
23. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S
Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
[TBL] [Abstract][Full Text] [Related]
25. Stool DNA methylation assays in colorectal cancer screening.
Kadiyska T; Nossikoff A
World J Gastroenterol; 2015 Sep; 21(35):10057-61. PubMed ID: 26401070
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
[TBL] [Abstract][Full Text] [Related]
27. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.
Sun G; Meng J; Duan H; Zhang D; Tang Y
Pathol Oncol Res; 2019 Oct; 25(4):1525-1534. PubMed ID: 30488278
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
[TBL] [Abstract][Full Text] [Related]
30. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer screening: An updated review of the available options.
Issa IA; Noureddine M
World J Gastroenterol; 2017 Jul; 23(28):5086-5096. PubMed ID: 28811705
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
33. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
34. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Berger BM; Schroy PC; Dinh TA
Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
[TBL] [Abstract][Full Text] [Related]
35. Colon Cancer Screening - Is It Time Yet?
Bhurgri H; Samiullah S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
[TBL] [Abstract][Full Text] [Related]
36. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location.
Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298
[TBL] [Abstract][Full Text] [Related]
37. A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2.
Zhao G; Ma Y; Li H; Li S; Zhu Y; Liu X; Xiong S; Liu Y; Miao J; Fei S; Zheng M; Zhao X
Clin Chim Acta; 2020 Apr; 503():84-89. PubMed ID: 31962098
[TBL] [Abstract][Full Text] [Related]
38. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update.
Molnár B; Galamb O; Kalmár A; Barták BK; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Dank M
Expert Rev Mol Diagn; 2019 Jun; 19(6):477-498. PubMed ID: 31046485
[No Abstract] [Full Text] [Related]
39. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study.
Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW
Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763
[TBL] [Abstract][Full Text] [Related]
40. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.
Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A
J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
